CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $25.81 ($281,729)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Executive Officer sold 76,420 shares at an average $26.32 ($2,011,197)
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $24.19 ($205,649)
- 4 Open-market buy Director bought 20,400 shares at $24.48 ($499,374)
- 4 Open-market buy Director bought 41,666 shares at an average $24.65 ($1,027,111)
- 4 Open-market buy Director bought 3,500 shares at $22.60 ($79,100)
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 4 Planned sale Chief Operating Officer sold 5,000 shares at $38.33 ($191,650)
- 424B5 Offering Prospectus
- 144 Insider Sale of Securities
- 8-K Event Other events
- 8-K Event Regulation FD disclosure · Other events
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $15.00 ($127,466)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Regulation FD disclosure
Page 7 of 13 · 253 filings